Peptide Monograph
LL-37
Cathelicidin Antimicrobial Peptide
At a Glance
Mechanism of Action
LL-37 is the only cathelicidin-derived antimicrobial peptide found in humans. It is a 37-amino acid peptide cleaved from the C-terminal end of the precursor protein hCAP18 (human cationic antimicrobial protein, 18 kDa) by the serine protease proteinase 3. The name "LL-37" derives from the two leucine residues at its N-terminus and its 37-amino acid length.[1]
The primary antimicrobial mechanism of LL-37 involves direct disruption of microbial membranes. As a cationic amphipathic peptide, LL-37 binds electrostatically to the negatively charged lipopolysaccharide (LPS) on gram-negative bacteria or lipoteichoic acid on gram-positive bacteria, then inserts into the lipid bilayer to form pores or otherwise disrupt membrane integrity. This mechanism is effective against both gram-positive and gram-negative bacteria, as well as certain fungi and enveloped viruses.[2]
Beyond direct antimicrobial killing, LL-37 functions as a critical modulator of the innate immune response. It acts as a chemoattractant for neutrophils, monocytes, and T-cells, recruiting immune cells to sites of infection. LL-37 promotes wound healing through stimulation of keratinocyte and fibroblast migration and proliferation, and enhances angiogenesis through FPRL1 (formyl peptide receptor-like 1) signaling.[2][3]
LL-37 exhibits potent anti-biofilm activity, disrupting established biofilms and preventing biofilm formation at sub-inhibitory concentrations. This property is of particular interest given the role of biofilms in chronic infections that are resistant to conventional antibiotics.[2]
The peptide plays a dual role in inflammation regulation. Depending on the tissue context, microenvironment, and concentration, LL-37 can be either pro-inflammatory (promoting cytokine release and immune cell activation) or anti-inflammatory (neutralizing LPS-induced inflammatory signaling and reducing endotoxin-mediated cytokine storms). This context-dependent immunomodulation is a defining feature of its biology.[3]
Critically, LL-37 expression is regulated by vitamin D. Liu et al. demonstrated in a landmark 2006 Science paper that activation of the vitamin D receptor (VDR) by 1,25-dihydroxyvitamin D3 directly upregulates transcription of the cathelicidin gene, establishing a molecular link between vitamin D status and innate immune defense.[4]
Evidence Summary
While LL-37 has an extensive basic science literature supporting its antimicrobial and immunomodulatory properties, clinical studies using exogenous LL-37 are limited primarily to topical wound healing applications. Subcutaneous use of synthetic LL-37 in humans is largely experimental and unapproved. The distinction between endogenous LL-37 biology and exogenous therapeutic application is critical.
Basic Science and In Vitro Studies
LL-37 has been extensively studied in vitro and demonstrates broad-spectrum antimicrobial activity against gram-positive bacteria (including MRSA), gram-negative bacteria (including Pseudomonas aeruginosa and E. coli), fungi (Candida species), and enveloped viruses. Zanetti and colleagues provided foundational work characterizing the cathelicidin family and LL-37's role in innate defense.[1]
Nizet et al. demonstrated using cathelicidin-knockout mouse models that endogenous cathelicidin is essential for defense against invasive skin infection by Group A Streptococcus, establishing a critical in vivo role for the peptide in innate immunity.[2] Agerberth and colleagues further characterized LL-37's role in mucosal defense and its regulation during infection and inflammation.[3]
Vitamin D Connection
The discovery by Liu et al. that toll-like receptor activation of human macrophages upregulates the vitamin D receptor and the vitamin D-1-hydroxylase gene, leading to induction of cathelicidin (LL-37) and killing of intracellular Mycobacterium tuberculosis, was published in Science in 2006. This work established a direct molecular link between vitamin D sufficiency and antimicrobial innate immune function.[4] This finding has significant implications for understanding susceptibility to infection in vitamin D-deficient populations.
Clinical Evidence
Clinical studies with exogenous LL-37 have focused primarily on topical wound healing applications. Early-phase clinical trials have explored LL-37 as a topical treatment for hard-to-heal venous leg ulcers, with some evidence of improved healing rates compared to placebo.[5]
Subcutaneous administration of synthetic LL-37 has generated interest in the Lyme disease and chronic infection communities, based on the peptide's anti-biofilm and antimicrobial properties. However, this use is entirely anecdotal and no controlled clinical studies have been published supporting systemic LL-37 administration for any infectious disease indication.
Primary Uses (in Research)
Based on the available literature, LL-37 has been investigated for the following applications:
- Antimicrobial defense — Broad-spectrum activity against bacteria, fungi, and enveloped viruses through direct membrane disruption.[1][2]
- Anti-biofilm activity — Disruption of established bacterial biofilms and prevention of biofilm formation, relevant to chronic and recalcitrant infections.[2]
- Wound healing — Promotion of keratinocyte migration, fibroblast proliferation, and angiogenesis in wound healing contexts. Topical clinical trials have shown early promise.[5]
- Innate immune modulation — Chemotaxis of immune cells, modulation of cytokine production, and enhancement of pathogen clearance.[3]
- LPS neutralization — Binding and neutralization of bacterial endotoxin (LPS), potentially reducing sepsis-related inflammatory cascades.[3]
Contraindications
No established human contraindications exist for exogenous LL-37 because insufficient clinical data is available. The following precautions are based on the peptide's known pharmacological mechanisms and represent theoretical concerns:
- Pregnancy and lactation — No reproductive toxicology or teratogenicity studies have been conducted with exogenous LL-37 in humans. No safety data exists for use during pregnancy or breastfeeding. Use is strongly discouraged.
- Autoimmune conditions — LL-37 is implicated in the pathogenesis of several autoimmune diseases, including psoriasis (where LL-37 complexed with self-DNA activates plasmacytoid dendritic cells) and systemic lupus erythematosus. Exogenous administration could theoretically exacerbate autoimmune flares.
- Hypersensitivity — LL-37 is an inherently inflammatory peptide at certain concentrations. Injection site reactions including pain, redness, and swelling are expected. Individuals with mast cell disorders or chronic urticaria should exercise particular caution.
- Rosacea — Elevated LL-37 levels have been implicated in the pathophysiology of rosacea. Exogenous LL-37 could theoretically worsen rosacea symptoms.
- Known hypersensitivity — Discontinue use if signs of systemic allergic reaction (widespread rash, urticaria, angioedema, dyspnea) develop.
Standard Protocols
The following protocols are derived from research study dosing and community-reported protocols. No dosing regimen for subcutaneous LL-37 has been validated in human clinical trials. These should not be interpreted as medical prescriptions.
| Protocol | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| Immune support (research) | SubQ | 50 – 100 mcg | 1x daily | 2–4 weeks |
| Low-dose protocol | SubQ | 50 mcg | Every other day | 4–6 weeks |
| Wound healing (topical) | Topical | Variable (0.5–1.6 mg/mL) | 1–2x daily application | Until wound closure |
Common Stacks & Synergies
In the peptide research and self-experimentation community, LL-37 is sometimes combined with other compounds. The following stacks are commonly discussed but have no published human clinical evidence supporting their combined use:
- LL-37 + Vitamin D3 — The most scientifically grounded combination. Vitamin D directly upregulates endogenous LL-37 production via the vitamin D receptor. Supplementing vitamin D3 (to achieve serum 25(OH)D levels of 40–60 ng/mL) may enhance the body's own cathelicidin production alongside exogenous LL-37.[4]
- LL-37 + BPC-157 — The rationale is that LL-37 provides antimicrobial and immune-modulating effects while BPC-157 promotes tissue repair through complementary angiogenic and growth-factor pathways.
- LL-37 + Thymosin Alpha-1 — Both peptides modulate innate and adaptive immunity. The combination targets different arms of immune function and is sometimes discussed in the context of chronic infection protocols.
Preparation & Administration
LL-37 is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 1 mg or 5 mg of peptide. It must be reconstituted with bacteriostatic water (BAC water) before injection.
Reconstitution
For a standard 5 mg vial reconstituted with 5 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 100 mcg. Adjust reconstitution volume to achieve desired concentration. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.
Injection
Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. Note that LL-37 is an inherently inflammatory peptide, and injection site reactions (pain, redness, swelling) are more common than with many other peptides. Rotate injection sites. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.
Topical Application
For wound healing applications, LL-37 has been formulated in wound dressings and topical solutions at concentrations of 0.5–1.6 mg/mL. Topical application avoids systemic exposure but limits effects to the local tissue environment. Compounding pharmacies may prepare topical LL-37 formulations.
Side Effects & Adverse Events
The adverse event profile described below is drawn from limited clinical wound healing studies, basic science literature, and uncontrolled self-reports. Without comprehensive human clinical trials of subcutaneous LL-37, the true incidence and severity of side effects cannot be established.
LL-37 is an endogenous human peptide, which theoretically reduces the risk of immunogenic reactions compared to non-human peptides. However, exogenous administration at pharmacological concentrations may produce effects distinct from endogenous expression levels.
Known and reported side effects:
- Injection site pain, redness, and swelling (expected and commonly reported; LL-37 is inherently pro-inflammatory at the injection site)
- Localized warmth and induration at injection site
- Potential for autoimmune flares in predisposed individuals (theoretical, based on LL-37's role in psoriasis and lupus pathogenesis)
- Headache (self-reported, unverified)
- Flu-like symptoms following initial doses (self-reported, possibly related to immune activation)
The theoretical risk of exacerbating autoimmune conditions (particularly psoriasis and rosacea) through exogenous LL-37 administration is the most significant safety concern raised by the basic science literature.[3]
Drug Interactions
No formal drug interaction studies have been conducted with exogenous LL-37 in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:
- Immunosuppressants (cyclosporine, tacrolimus, biologics) — LL-37's immune-activating properties could theoretically counteract the effects of immunosuppressive medications. Use in transplant recipients or individuals on immunosuppressive therapy is not recommended.
- Corticosteroids — Systemic corticosteroids suppress cathelicidin expression. Concurrent use with exogenous LL-37 may produce opposing effects on immune function.
- Vitamin D supplements — Vitamin D upregulates endogenous LL-37 production. Co-administration may produce additive immune effects, which could be beneficial or excessive depending on context.[4]
- Antibiotics — LL-37 may have synergistic antimicrobial effects with certain conventional antibiotics, though this has only been demonstrated in vitro.
- TNF-alpha inhibitors (adalimumab, infliximab) — LL-37 can promote TNF-alpha production. Concurrent use with TNF inhibitors may produce unpredictable immune modulation.
Storage & Handling
| Form | Condition | Stability |
|---|---|---|
| Lyophilized powder (sealed) | Frozen (−20°C / −4°F) | Optimal for long-term storage (months to years) |
| Lyophilized powder (sealed) | Refrigerated (2–8°C / 36–46°F) | Stable for weeks to months |
| Reconstituted solution | Refrigerated (2–8°C / 36–46°F) | Use within 14 days (LL-37 is susceptible to protease degradation) |
| Reconstituted solution | Room temperature | Not recommended; use within hours if unavoidable |
LL-37 is more susceptible to degradation than many smaller peptides due to its larger size and susceptibility to protease activity. Frozen storage of lyophilized powder is recommended for long-term stability. Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.
Legal & Regulatory Status
- FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Active research interest in wound healing and anti-infective applications. Sold as a research chemical.
- EMA (European Union) — Not approved as a medicinal product. Clinical trials for topical wound healing applications have been conducted in European settings.
- WADA (World Anti-Doping Agency) — Not specifically listed on the WADA Prohibited List as of 2026.
- Australia (TGA) — Not approved. Likely classified as a prescription-only substance under the Poisons Standard.
- Active research — LL-37 and its derivatives are subjects of active pharmaceutical development for wound healing, anti-infective, and anti-biofilm applications. Several LL-37-derived peptides are in preclinical and early clinical development.
Open Questions
Significant gaps remain in the exogenous LL-37 evidence base. Key unresolved questions include:
- Systemic vs. local effects — Whether subcutaneous administration produces meaningful systemic antimicrobial or immunomodulatory effects, or whether the peptide is too rapidly degraded by proteases to reach effective concentrations at distant sites.
- Autoimmune risk — Given LL-37's established role in the pathogenesis of psoriasis, rosacea, and lupus, the risk of exogenous administration triggering or exacerbating autoimmune conditions requires clarification.
- Optimal dosing for systemic use — Subcutaneous dosing protocols are entirely empirical. The pharmacokinetics of injected LL-37, including bioavailability, tissue distribution, and protease degradation rate in vivo, are poorly characterized.
- Resistance development — Whether chronic exogenous LL-37 use could promote bacterial resistance to antimicrobial peptides, potentially compromising endogenous innate immune defense.
- Chronic infection efficacy — Anecdotal interest in LL-37 for Lyme disease and other chronic infections is not supported by clinical data. Whether LL-37 can penetrate biofilms in vivo at achievable tissue concentrations is unknown.
- Purity and quality control — As an unregulated research chemical, the purity, sterility, and accurate labeling of commercially available LL-37 products cannot be guaranteed. Synthesis of a 37-amino acid peptide is technically demanding, increasing the risk of impurities.
Bibliography
- Zanetti M. "Cathelicidins, multifunctional peptides of the innate immunity." J Leukoc Biol. 2004;75(1):39-48. doi:10.1189/jlb.0403147. PMID:12960280.
- Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, Pestonjamasp V, Piraino J, Huttner K, Gallo RL. "Innate antimicrobial peptide protects the skin from invasive bacterial infection." Nature. 2001;414(6862):454-7. doi:10.1038/35106587. PMID:11719807.
- Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH. "The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations." Blood. 2000;96(9):3086-93. doi:10.1182/blood.V96.9.3086. PMID:11049988.
- Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response." Science. 2006;311(5768):1770-3. doi:10.1126/science.1123933. PMID:16497887.
- Gronberg A, Mahlapuu M, Stahle M, Whately-Smith C, Rollman O. "Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial." Wound Repair Regen. 2014;22(5):613-21. doi:10.1111/wrr.12211. PMID:25041740.